Core Insights - CollPlant Biotechnologies is strategically positioning its photocurable dermal filler platform to address facial volume loss associated with GLP-1 weight-loss therapies, targeting a growing market of patients experiencing facial fat depletion due to rapid weight loss [1][2] Group 1: Product Development - The photocurable dermal filler is designed to restore facial volume while providing a supportive regenerative matrix that integrates with surrounding tissue [1] - This technology aims to provide immediate structural restoration and support tissue integration, potentially improving skin quality and elasticity over time [1] - CollPlant's filler technology is currently in the preclinical stage, as part of a broader strategy to develop next-generation regenerative aesthetic solutions based on recombinant human collagen (rhCollagen) [1] Group 2: Market Opportunity - The rapid global adoption of GLP-1 therapies is driving increased demand for aesthetic solutions that address changes in facial structure following significant weight loss [1] - There is a growing interest in non-surgical treatments that restore volume while maintaining natural facial dynamics, indicating a shift in patient preferences [1] - CollPlant's regenerative biomaterial platform positions the company to meet this emerging clinical and aesthetic need [1] Group 3: Strategic Partnerships - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, which is a leader in the dermal filler market [1]

Company Overview - CollPlant Biotechnologies is a regenerative and aesthetics medicine company focused on developing technologies and products based on non-animal-derived recombinant human collagen (rhCollagen) [1][3] - The company specializes in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics [3] Recent Developments - CollPlant will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8th and 9th, 2025, at the Lotte New York Palace Hotel [1] - Investors can request one-on-one meetings with CollPlant representatives during the conference [2] Strategic Partnerships - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a subsidiary of AbbVie, which is a leader in the dermal filler market [4]